Multihance at 3 Tesla (3T) in Brain Tumors

A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T

Compare the efficacy of MultiHance and Magnevist

The purpose of this study was to evaluate whether Multihance is superior to Magnevist in terms of qualitative and quantitative assessment of unenhanced MRI and contrast-enhanced MRI for the visualization of brain disease.

Inclusion Criteria:

• Was 18 years or older
• Provided written informed consent
• Scheduled for MRI
• Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI exams within 14 days

Exclusion Criteria:

• Pregnant or lactating females
• Allergy to one or more of the ingredients in the products or hypersensitivity to any metals
• Congestive heart failure, class IV
• Previous stroke in the past year
• Received another contrast agent within 24 hours pre and post each exam
• Investigational product
• Contraindications to MRI
• Severe claustrophobia
• Surgery with 3 weeks prior
• Steroid therapy or radiosurgery between two exams